Benefit‐Risk Assessment of Current Antiarrhythmic Drug Therapy of Atrial Fibrillation

gan Hohnloser, Stefan H.
Cyhoeddwyd yn Clin Cardiol (2012)

Atrial Fibrillation: Is Rate Stabilization a Valid Clinical Strategy?

gan Hohnloser, Stefan H.
Cyhoeddwyd yn Ann Noninvasive Electrocardiol (2006)

Usefulness of Risk Stratification for Future Cardiac Events in Infarct Survivors with Severely Depressed Versus Near‐Normal Left Ventricular Function: Results From a Prospective Lo...

gan Klingenheben, Thomas, Hohnloser, Stefan H.
Cyhoeddwyd yn Ann Noninvasive Electrocardiol (2003)

Optimal Anticoagulation Strategy for Cardioversion in Atrial Fibrillation

gan Bushoven, Philipp, Linzbach, Sven, Vamos, Mate, Hohnloser, Stefan H
Cyhoeddwyd yn Arrhythm Electrophysiol Rev (2015)

Syncope on exertion in a young male

gan Erath, Julia W., Puntmann, Valentina O., Chavakis, Emmanouil, Hohnloser, Stefan H.
Cyhoeddwyd yn HeartRhythm Case Rep (2018)

Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta...

gan Vamos, Mate, Cappato, Riccardo, Marchlinski, Francis E., Natale, Andrea, Hohnloser, Stefan H.
Cyhoeddwyd yn Europace (2016)

N-Terminal Arginines Modulate Plasma-Membrane Localization of Kv7.1/KCNE1 Channel Complexes

gan Girmatsion, Zenawit, Biliczki, Peter, Takac, Ina, Schwerthelm, Christin, Hohnloser, Stefan H., Ehrlich, Joachim R.
Cyhoeddwyd 2011

Assessment of Microvolt T‐Wave Alternans in High‐Risk Patients with the Congenital Long‐QT Syndrome

gan Schmitt, Jörn, Baumann, Stefan, Klingenheben, Thomas, Richter, Sergio, Duray, Gabor, Hohnloser, Stefan H., Ehrlich, Joachim R.
Cyhoeddwyd yn Ann Noninvasive Electrocardiol (2009)

Cellular electrophysiology of canine pulmonary vein cardiomyocytes: action potential and ionic current properties

gan Ehrlich, Joachim R, Cha, Tae-Joon, Zhang, Liming, Chartier, Denis, Melnyk, Peter, Hohnloser, Stefan H, Nattel, Stanley
Cyhoeddwyd 2003

Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)

gan Connolly, Stuart J., Eikelboom, John, Dorian, Paul, Hohnloser, Stefan H., Gretler, Daniel D., Sinha, Uma, Ezekowitz, Michael D.
Cyhoeddwyd 2013

Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from the ATHENA study

gan Blomström‐Lundqvist, Carina, Marrouche, Nassir, Connolly, Stuart, Corp dit Genti, Valérie, Wieloch, Mattias, Koren, Andrew, Hohnloser, Stefan H.
Cyhoeddwyd yn Clin Cardiol (2020)

Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study

gan Torp-Pedersen, Christian, Crijns, Harry J.G.M., Gaudin, Christophe, Page, Richard L., Connolly, Stuart J., Hohnloser, Stefan H.
Cyhoeddwyd 2011

Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation/flutter: Insights from the ATHENA study

gan Vamos, Mate, Calkins, Hugh, Kowey, Peter R., Torp‐Pedersen, Christian T., Corp dit Genti, Valérie, Wieloch, Mattias, Koren, Andrew, Hohnloser, Stefan H.
Cyhoeddwyd yn Clin Cardiol (2019)

Dronedarone in patients with congestive heart failure: insights from ATHENA

gan Hohnloser, Stefan H., Crijns, Harry J.G.M., van Eickels, Martin, Gaudin, Christophe, Page, Richard L., Torp-Pedersen, Christian, Connolly, Stuart J.
Cyhoeddwyd 2010

Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial

gan Pisters, Ron, Hohnloser, Stefan H., Connolly, Stuart J., Torp-Pedersen, Christian, Naditch-Brûlé, Lisa, Page, Richard L., Crijns, Harry J.G.M.
Cyhoeddwyd 2014

Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the R...

gan Hohnloser, Stefan H., Calkins, Hugh, Willems, Stephan, Verma, Atul, Schilling, Richard, Okumura, Ken, Nordaby, Matias, Kleine, Eva, Biss, Branislav, Gerstenfeld, Edward P.
Cyhoeddwyd yn J Interv Card Electrophysiol (2019)

Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study

gan Calkins, Hugh, Willems, Stephan, Verma, Atul, Schilling, Richard, Hohnloser, Stefan H, Okumura, Ken, Nordaby, Matias, Kleine, Eva, Bis, Branislav, Gerstenfeld, Edward P
Cyhoeddwyd yn Europace (2019)

Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES

gan Benz, Alexander P., Eikelboom, John W., Yusuf, Salim, Hohnloser, Stefan H., Kahl, Anja, Beresh, Heather, Balasubramanian, Kumar, Healey, Jeff S., Connolly, Stuart J.
Cyhoeddwyd yn Thromb Haemost (2021)

Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT...

gan Hohnloser, Stefan H., Cappato, Riccardo, Ezekowitz, Michael D., Evers, Thomas, Sahin, Kurtulus, Kirchhof, Paulus, Meng, Isabelle Ling, van Eickels, Martin, Camm, A. John
Cyhoeddwyd yn Europace (2016)

Uninterrupted anticoagulation with non‐vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials

gan Cardoso, Rhanderson, Willems, Stephan, Gerstenfeld, Edward P., Verma, Atul, Schilling, Richard, Hohnloser, Stefan H., Okumura, Ken, Nordaby, Matias, Brouwer, Marc A., Calkins, Hugh
Cyhoeddwyd yn Clin Cardiol (2018)